Literature DB >> 30112577

Prazosin during fear conditioning facilitates subsequent extinction in male C57Bl/6N mice.

Elizabeth K Lucas1,2, Wan-Chen Wu1, Ciorana Roman-Ortiz1, Roger L Clem3,4.   

Abstract

RATIONALE: Recovery from a traumatic experience requires extinction of cue-based fear responses, a process that is impaired in post-traumatic stress disorder. While studies suggest a link between fear behavioral flexibility and noradrenaline signaling, the role of specific receptors and brain regions in these effects is unclear.
OBJECTIVES: Here, we examine the role of prazosin, an α1-adrenergic receptor (α1-AR) antagonist, in auditory fear conditioning and extinction.
METHODS: C57Bl/6N mice were subjected to auditory fear conditioning and extinction in combination with systemic (0.1-2 mg/kg) or local microinjections (3 or 6 mM) of the α1-AR antagonist prazosin into the prelimbic division of medial prefrontal cortex or basolateral amygdala. Conditioned fear and anxiety-like behaviors were compared with vehicle-injected control animals.
RESULTS: Mice that received systemic prazosin prior to fear conditioning exhibited similar initial levels of cue-elicited freezing compared to vehicle controls on the following day. However, at all doses tested, fear that was acquired during prazosin treatment was more readily extinguished, whereas anxiety-like behavior on the day of extinction was unaffected. A similar pattern of results was observed when prazosin was microinjected into the basolateral amygdala but not the prelimbic cortex. In contrast to pre-conditioning injections, prazosin administration prior to extinction had no effect on freezing.
CONCLUSIONS: Our results indicate that α1-AR activity during aversive conditioning is dispensable for memory acquisition but renders conditioned fear more impervious to extinction. This suggests that behavioral flexibility is constrained by noradrenaline at the time of initial learning via activation of a specific AR isoform.

Entities:  

Keywords:  ADRA1A; Exposure therapy; Terazosin

Mesh:

Substances:

Year:  2018        PMID: 30112577      PMCID: PMC6374171          DOI: 10.1007/s00213-018-5001-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  5 in total

1.  Interleukin-4 signalling pathway underlies the anxiolytic effect induced by 3-deoxyadenosine.

Authors:  Tangxin Gao; Bai Li; Yangyang Hou; Shaolei Luo; Lei Feng; Jun Nie; Yi Ma; Le Xiao; Xu Chen; Hongkun Bao; Xianmin Lu; Feilong Huang; Gang Wang; Chunjie Xiao; Jing Du
Journal:  Psychopharmacology (Berl)       Date:  2019-04-08       Impact factor: 4.530

2.  Phasic and Tonic Locus Coeruleus Stimulation Associated Valence Learning Engages Distinct Adrenoceptors in the Rat Basolateral Amygdala.

Authors:  Tamunotonye Omoluabi; Kyron D Power; Tayebeh Sepahvand; Qi Yuan
Journal:  Front Cell Neurosci       Date:  2022-05-09       Impact factor: 6.147

3.  The Neurochemical Effects of Prazosin Treatment on Fear Circuitry in a Rat Traumatic Stress Model.

Authors:  Sema Ketenci; Nazife Gökçe Acet; Gökçe Elif Sarıdoğan; Banu Aydın; Hülya Cabadak; Mehmet Zafer Gören
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-05-31       Impact factor: 2.582

4.  Editorial: the psychopharmacology of extinction-from theory to therapy.

Authors:  Amy L Milton; Andrew Holmes
Journal:  Psychopharmacology (Berl)       Date:  2019-01       Impact factor: 4.530

5.  Prazosin use in a patient with rare Neurobeachin gene deletion shows improvement in paranoid behavior: a case report.

Authors:  Christina Y Cantwell; Jamie Fortman; Alexis Seegan
Journal:  J Med Case Rep       Date:  2021-12-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.